For the quarter ending 2025-09-30, NVCR had $192,505K increase in cash & cash equivalents over the period. $14,919K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -37,270 | -74,458 |
| Depreciation and amortization | 3,663 | 6,769 |
| Accrued interest | 789 | 3,647 |
| Asset write-downs and impairment of field equipment | 230 | 2,685 |
| Share-based compensation | 29,321 | 55,695 |
| Foreign currency remeasurement loss (gain) | -890 | -1,322 |
| Decrease (increase) in accounts receivables and prepaid expenses | -3,577 | 19,053 |
| Amortization of discount (premium) | -6,402 | -13,114 |
| Decrease (increase) in inventories | -886 | 4,570 |
| Decrease (increase) in other long-term assets | -2,490 | -3,990 |
| Increase (decrease) in accounts payables and accrued expenses | 24,830 | -14,313 |
| Increase (decrease) in other long-term liabilities | -2,430 | -201 |
| Net cash provided by (used in) operating activities | 20,574 | -51,601 |
| Purchase of property, equipment and field equipment | 5,655 | 16,097 |
| Proceeds from maturity of short-term investments | 185,000 | 540,000 |
| Purchase of short-term investments | 107,909 | 494,389 |
| Net cash provided by (used in) investing activities | 71,436 | 29,514 |
| Proceeds from issuance of shares, net | 0 | 2,136 |
| Proceeds from senior secured credit facility, net | 99,979 | 0 |
| Repayment and redemption of long-term debt | 0 | 0 |
| Exercise of options | 538 | 5,498 |
| Net cash provided by (used in) financing activities | 100,517 | 7,634 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -22 | 492 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 192,505 | -13,961 |
| Cash and cash equivalents at beginning of period | 166,094 | - |
| Cash and cash equivalents at end of period | 344,638 | - |
NovoCure Ltd (NVCR)
NovoCure Ltd (NVCR)